Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Macy's CEO Tony Spring, who is trying to turn around the company, wants to prove to the public markets that its three-brand ...
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
Oppenheimer initiated coverage of Compugen (CGEN) with an Outperform rating and $4 price target. With a sole oncology focus, Compugen is ...
Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...